Improving Cholesterol Treatment for Heart Disease
This study is looking for better ways to help people with, or at high risk for, atherosclerosis (cholesterol buildup in the arteries) manage their cholesterol. It compares two approaches: a "Referral to Pharmacist-Driven Medication Management Program" where pharmacists help adjust lipid-lowering medications, and a "Best-Practice Alert" system that sends notifications to doctors through electronic health records. The study aims to enroll about 300 adults aged 18 to 95 who have established heart disease, diabetes, possible familial hypercholesterolemia, or are at high risk. Success will be measured by how many participants reach their target LDL-C (bad cholesterol) levels after 6 months. The current recruitment status is unclear.
- Study design
- This interventional study plans to enroll about 300 participants. It uses a systematic allocation at the provider level, meaning doctors are assigned to one of two strategies.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for 6 months after notification to measure their LDL-C levels.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Improving Lipid Optimization Quality and Treatment Options in ASCVD
At a glance
Conditions
NCT06960655
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Brigham and Women's Hospital
Boston, Massachusettsno site contact published
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Benjamin Scirica, M.D., MPH · PRINCIPAL_INVESTIGATOR · Brigham and Women's Hospital
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Want this trial checked against your situation?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Achieving Goal LDL-C6 months after notification
% of participants who achieve LDL-c goal (\<100 mg/dL for high-risk primary prevention, \<70 mg/dL for patients with established ASCVD)